Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
3 reports, 2 independent
Updated Oct 8
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Corcept Therapeutics disclosed insider trading activity via SEC filings.Sub-event
Details of investor buying and insider sales in Corcept Therapeutics stock revealed in SEC filings.1 source
Keep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
-
SEC
Slovak company
Related events
- Corcept Therapeutics and Halozyme Therapeutics are identified as top holdings in specific U.S. small-cap ETFs.
- Royal Bank of Canada increased its holdings in a Vanguard ETF while the SEC mandated 13F filings for institutional holdings.
- Royal Bank of Canada and Stonehearth Capital Management purchased new stakes in the Fidelity Momentum Factor ETF.
- RBC decreased target price and rating on fund (Q5908002), while TD Cowen restated its rating on shares.